|This article needs additional citations for verification. (July 2007)|
CSL Behring is one of the world's leading plasma protein biotherapeutics companies. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures a range of plasma-derived and recombinant therapies worldwide. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies (PIDD); hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.
|Headquarters||King of Prussia, Pennsylvania|
|Key people||Paul Perreault, CEO and Managing Director of CSL Limited|
Parent Company: CSL Limited, (ASX:CSL), Melbourne, Australia
Headquarters: King of Prussia, PA
Operations: In 27 countries
CEO and Managing Director: Paul Perreault
R&D: Marburg, Germany; Bern, Switzerland; King of Prussia, Pennsylvania, USA; Tokyo, Japan; Broadmeadows and Parkville, Victoria, Australia.
CSL Behring is a member of the CSL Group of companies. Parent company CSL Limited (ASX: CSL) is a specialty biopharmaceutical company headquartered in Parkville, Australia. As part of a global alignment, the CSL Behring brand was established in 2007. Previously known as ZLB Behring, the company has a long history dating back to 1904.
1904: Emil von Behring founded the Behringwerke in Marburg, Germany, for the purpose of experimental work on disease prevention and for the manufacture of sera and vaccines.
1913: Behringwerke expands to produce a gas gangrene antiserum and a cholera vaccine.
1916: CSL (then Commonwealth Serum Laboratories) was established in Australia with the goal of providing vaccines to the people of Australia and New Zealand.
1917: CSL produces 3 million doses of a mixed bacterial vacine to combat the 1919 influenza pandemic.
1930: CSL releases its first life-saving antivenom for tiger snake bites.
1944: CSL begins producing penicillin on a large scale for the military and Australia is the first country to supply the drug to civilians at no charge.
1949: ZLB (Zentrallaboratorium Blutspendedienst, a predecessor company) is established in Bern, Switzerland, as a department of the Swiss Red Cross and holds its first donor blood sessions in Switzerland.
1954: Australian CSL officer Val Bazeley assists Jonas Salk with the production of the experimental polio vaccine used in the first clinical trials in the US. Bazeley returns to Australia to set up production of the Salk vaccine at CSL.
1966: Rh(D) immunoglobulin, produced from plasma, is introduced by CSL for haemolytic disease in newborns.
1991: CSL Limited is incorporated in Australia.
2000: ZLB Bioplasma (a predecessor company) is established, acquiring the plasma fractionation assets from SRK, a nonprofit organization affiliated with the Swiss Red Cross. ZLB becomes the fifth largest manufacturer of plasma products worldwide.
2001: Aventis Behring (a predecessor company) acquires 42 plasma centers, forming the world's largest plasma collection business.
2004: CSL Limited completes the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring (later CSL Behring).
2007: ZLB Behring becomes CSL Behring.
2009: ZLB Plasma changes its name to CSL Plasma to align with its parent company, CSL Behring, and opens the world's largest and most advanced plasma testing laboratories in Knoxville, Tennessee.
2009: National Organization for Rare Disorders (NORD) recognized CSL Behring for developing and marketing the first and only treatment in the U.S. for acute bleeding episodes in patients with congenital fibrinogen deficiency, an extremely rare, potentially life-threatening bleeding disorder.
2009: CSL Behring awarded the Swiss government's Tell Award for exceptional innovations in state-of-the-art manufacturing and novel protein therapies.
2012: The European Organisation for Rare Disorders recognized CSL Behring for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions with the 2012 EURORDIS Award.
CSL Behring researches, develops, manufactures and markets a range of plasma-derived and recombinant products and related services, specializing in the treatment of rare and serious diseases. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies; hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.
- Hizentra®,Human normal immunoglobulin. Liquid 20% immunoglobulin solution, ready-to-use for subcutaneous administration
- Privigen®, human polyvalent immunoglobulin, liquid 10% solution for intravenous injection
- Carimune® NF, Sandoglobulin®, Sanglopor® human normal immunoglobulin, freeze-dried formulations for intravenous administration
- Rhophylac® human anti-D immunoglobulin. Prefilled syringes of highly purified anti-Rhesus factor D IgG for intravenous administration and intramuscular injection.
- Cytogam®, human cytomegalovirus immunoglobulin. Liquid immunoglobulin containing a standardized amount of antibody to cytomegalovirus.
- Berirab® P, human rabies immunoglobulin, liquid 16% solution for intramuscular injection
- Beriglobin® P, human hepatitis A immunoglobulin, liquid 16% solution for intramuscular injection
- Hepatitis B Immunoglobulin P Behring, human hepatitis B immunoglobulin, liquid 16% solution for intramuscular injection
- Tetagam® P, human tetanus immunoglobulin, liquid 16% solution for intramuscular injection
- Varicellon® P, human varicella immunoglobulin, liquid 16% solution for intramuscular injection
- Beriate®, freeze-dried human coagulation factor VIII concentrate
- Berinin® P, freeze-dried human coagulation factor IX concentrate
- Helixate® FS and Helixate® NexGen, freeze-dried recombinant coagulation factor VIII
- RiaSTAP® human coagulation factor I, freeze-dried factor I concentrate
- Humate-P® and Haemate® P, freeze-dried human coagulation factor VIII: C and von Willebrand factor concentrate
- Monoclate P®, a freeze-dried monoclonal antibody purified human coagulation factor VIII concentrate
- Mononine®, a freeze-dried human coagulation factor IX that has been purified using monoclonal antibodies
- Stimate®, a synthetic desmopressin acetate nasal spray
- Factor X P Behring, a freeze-dried human coagulation factor IX and factor X concentrate
- Fibrogammin® P and Corifact™, freeze-dried human coagulation factor XIII concentrate
- Octostim®, a synthetic desmopressin acetate nasal spray
- Zemaira®, freeze-dried Human Alpha1-proteinase inhibitor (A1-PI)
- Beriplex® P/N, Kcentra™, freeze-dried human prothrombin complex concentrate
- Haemocomplettan® P, RiaSTAP™, freeze-dried human fibrinogen (factor I) concentrate
- Kybernin® P, freeze-dried human antithrombin III concentrate
- AlbuRx®, Alburex, Human Albumin Behring, Albuminar®, human albumin solution (5%, 20% or 25% human albumin solutions)
- Berinert® P, freeze-dried human C1-esterase inhibitor (C1-INH) concentrate
- Streptase®, freeze-dried streptokinase
- Beriplast® P Combi-Set, fibrin sealant kit, freeze-dried fibrin sealant for topical application
- Fibrogammin® P, freeze-dried human coagulation factor XIII concentrate
- TachoComb®, fibrin sealant fleece-type, fleece-type collagen preparations coated with fibrin glue components
(Note: Product availability varies from country to country, depending on registration status.)
The company is headquartered in King of Prussia, Pennsylvania. It has 11,000+ employees in 27 countries. Major manufacturing centers are located in Bern, Switzerland, Marburg, Germany, Kankakee, Illinois, and Broadmeadows, Australia.
- Official Website
- Parent Company (CSL Limited)
- CSL Plasma
- Customer Service
- Biography of Emil von Behring